CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a $4.4 billion gene editing company whose stock has surged over 21% year-to-date according to InvestingPro data, reported new Phase 1 ...

Furthermore, CRISPR Therapeutics plans to release initial Phase 1 data for its cardiovascular assets and longer-term follow-up data for its next-generation CD19 CAR T therapy by mid-2025. Additionally ...

The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...

-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...

CRISPR gene editing technology is making a name as a genetic swiss army knife. The genetics research community, seemingly limited by only their imagination, have been creating CRISPR applications at a ...

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new ...